Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Pharmaceuticals announced that four abstracts for its approved drug Revuforj (revumenib) have been accepted for presentation at the ASCO 2026 Annual Meeting. The highlight is an oral presentation of safety and efficacy data from 21 adults and children with acute leukemia who received revumenib as maintenance therapy following hematopoietic stem cell transplantation.
Key figures
- Drug Name
- Revuforj (revumenib)
- Abstract count
- 4
- Oral presentation patient count
- 21
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.